© 2025 MJH Life Sciences™ , Patient Care Online – Primary Care News and Clinical Resources. All rights reserved.
Latest Conference Articles
Daniel Butler, MD: Pearls for Primary Care When Treating and Referring Older Adults for Chronic Itch
March 9th 2025
Butler addresses how primary care can help manage the burdens of itch in their older patients and offers pearls for consulting and referring to dermatology.
Rocatinlimab, an OX40 Inhibitor, Achieves Positive Results in Atopic Dermatitis Treatment: ROCKET-Horizon Topline Findings
March 9th 2025
Approximately one-third of participants treated with rocatinlimab achieved EASI-75 at 24 weeks, more than 2 times the proportion in the placebo group, among other robust findings.
Atopic Dermatitis Breakthrough: Linda Stein Gold, MD, on Tapinarof's Treatment-Free Benefits
March 9th 2025
AAD 2025. Linda Stein Gold, MD, FAAD, discusses the late-breaking tapinarof cream 1% data from a new analysis of the ADORING-3 clinical trial.
Benjmain Ungar, MD: Addressing the Immunological Causes of Seborrheic Dermatitis
March 9th 2025
Benjamin Ungar, MD, discusses his presentation at AAD 2025 covering advances and updates about rosacea and seborrheic dermatitis.
Dupilumab Demonstrates Superior Long-Term Persistence Over Upadacitinib and Tralokinumab in Atopic Dermatitis
March 9th 2025
Dupilumab was associated with the highest drug survival in monotherapy with nearly 90% of study participants remaining on treatment at both 12 and 24 months.
Atopic Dermatitis: Investigational Anti-OX40L Antibody Shows Sustained Itch Relief, Even After Discontinuation
March 8th 2025
AAD 2025: In a post hoc analysis of the STREAM-AD Phase 2b study, 63% of patients with AD maintained itch reduction even after stopping amlitelimab use.
Atopic Dermatitis: It’s Not the Food, I Promise You
March 8th 2025
AAD 2025. Peter Lio, MD, from the Feinberg School of Medicine in Chicago, says, skip the elimination diet because food is rarely a cause of atopic dermatitis.
Ruxolitinib Cream 1.5% Demonstrates Efficacy in Prurigo Nodularis: Phase 3 Findings
March 8th 2025
Data from the TRuE-PN trial program were presented at the 2025 American Academy of Dermatology Annual Meeting in Orlando, offering important insights into potential new therapeutic options for this debilitating condition.
Rocatinlimab Shows Significant Efficacy in Moderate to Severe Atopic Dermatitis: Phase 3 IGNITE Trial Results
March 8th 2025
AAD 2025: The IGNITE study of the OX40 inhibitor included adults previously treated with a biologic or systemic JAK inhibitor, according to Amgen and Kyowa Kirin.
Icotrokinra Shows Promise for Moderate-to-Severe Plaque Psoriasis in Phase 3 Trials
March 8th 2025
Icotrokinra is the first targeted oral peptide designed to selectively block the IL-23 receptor, which is implicated in multiple inflammatory conditions including plaque psoriasis.